{"title":"Fingolimod: new oral treatment for multiple sclerosis","authors":"David Rog MD, MRCP","doi":"10.1002/fps.73","DOIUrl":null,"url":null,"abstract":"<p><b>Fingolimod, a sphingosine-1-phosphate receptor modulator, is a novel oral treatment for multiple sclerosis. In this Drug profile the author reviews its mode of action, likely positioning and the advantages that it might offer in terms of clinical management of multiple sclerosis, and begins by setting the treatment context.</b></p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 1","pages":"6-12"},"PeriodicalIF":0.0000,"publicationDate":"2011-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.73","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.73","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Fingolimod, a sphingosine-1-phosphate receptor modulator, is a novel oral treatment for multiple sclerosis. In this Drug profile the author reviews its mode of action, likely positioning and the advantages that it might offer in terms of clinical management of multiple sclerosis, and begins by setting the treatment context.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
